XML 196 R16.htm IDEA: XBRL DOCUMENT v3.22.4
Other Disclosures (Tables)
12 Months Ended
Dec. 31, 2022
Other Disclosures  
Summary of remuneration of the Board of Directors and Executive Management

(DKK million)

2022

2021

2020

Wages and salaries

55

51

48

Share-based compensation expenses

70

58

43

Defined contribution plans

2

2

2

Total

127

111

93

Schedule of Remuneration to the Board of Directors

Base Board Fee

Committee
Fees

Share-Based Compensation Expenses

Total

(DKK million)

2022

2021

2020

2022

2021

2020

2022

2021

2020

2022

2021

2020

Deirdre P. Connelly

1.2

1.2

1.1

0.5

0.5

0.5

0.9

0.7

0.7

2.6

2.4

2.3

Pernille Erenbjerg

0.9

0.9

0.7

0.4

0.4

0.4

0.7

0.5

0.4

2.0

1.8

1.5

Anders Gersel Pedersen

0.6

0.6

0.4

0.4

0.4

0.4

0.5

0.4

0.5

1.5

1.4

1.3

Paolo Paoletti

0.6

0.6

0.4

0.3

0.3

0.3

0.5

0.4

0.4

1.4

1.3

1.1

Rolf Hoffmann

0.6

0.6

0.4

0.3

0.4

0.3

0.5

0.4

0.5

1.4

1.4

1.2

Elizabeth O’Farrell1

0.5

-

-

0.2

-

-

0.6

-

-

1.3

-

-

Jonathan Peacock2

-

0.5

0.3

-

0.3

0.3

-

0.6

0.4

-

1.4

1.0

Mats Pettersson3

-

-

0.3

-

-

0.1

-

-

1.6

-

-

2.0

Mijke Zachariasse4

0.6

0.6

0.4

-

-

-

0.4

0.3

0.1

1.0

0.9

0.5

Martin Schultz4

0.5

-

-

-

-

-

-

-

-

0.5

-

-

Takahiro Hamatani4

0.5

-

-

-

-

-

-

-

-

0.5

-

-

Peter Storm Kristensen5

0.1

0.6

0.4

-

-

-

0.1

0.4

0.4

0.2

1.0

0.8

Rima Bawarshi Nassar5,6

0.1

0.6

0.1

-

-

-

0.1

0.2

-

0.2

0.8

0.1

Daniel J. Bruno6

-

-

0.3

-

-

-

-

-

(0.4)

-

-

(0.1)

Total

6.2

6.2

4.8

2.1

2.3

2.3

4.3

3.9

4.6

12.6

12.4

11.7

Schedule of executive compensation

Base Salary

Defined Contribution Plans

Other Benefits

Annual Cash Bonus

Share-Based Compensation Expenses

Total

(DKK million)

2022

2021

2020

2022

2021

2020

2022

2021

2020

2022

2021

2020

2022

2021

2020

2022

2021

2020

Jan van de Winkel

8.6

7.9

7.3

1.3

1.1

1.0

0.3

0.6

1.0

8.6

7.9

8.4

22.9

20.6

19.6

41.7

38.1

37.3

Anthony Pagano1

4.3

3.2

3.0

0.1

0.1

0.1

-

-

-

2.6

1.9

2.3

9.5

7.2

5.2

16.5

12.4

10.6

Anthony Mancini2

4.7

3.9

3.1

0.1

0.1

0.1

-

3.1

3.3

2.8

2.3

2.0

11.4

7.2

3.1

19.0

16.6

11.6

Judith Klimovsky

4.9

4.0

4.0

0.1

0.1

0.1

-

-

0.1

2.9

2.5

3.0

14.1

13.2

12.7

22.0

19.8

19.9

Tahamtan Ahmadi3

4.6

3.3

-

0.1

0.1

-

-

-

-

2.8

2.0

-

7.7

5.5

-

15.2

10.9

-

David A. Eatwell1

-

-

0.9

-

-

0.1

-

-

2.5

-

-

-

-

-

(2.3)

-

-

1.2

Total

27.1

22.3

18.3

1.7

1.5

1.4

0.3

3.7

6.9

19.7

16.6

15.7

65.6

53.7

38.3

114.4

97.8

80.6

1 – David A. Eatwell stepped down as CFO on February 29, 2020, and Anthony Pagano was appointed CFO and member of the Executive Management on March 1, 2020.

2 – Anthony Mancini was appointed Chief Operating Officer and member of the Executive Management in March 2020.

3 – Tahamtan Ahmadi was appointed Chief Medical Officer, Head of Experimental Medicines and member of the Executive Management in March 2021.

Summary of fees to auditors

(DKK million)

2022

2021

2020

PricewaterhouseCoopers

Audit fees

5.8

5.8

4.9

Audit-related fees

2.0

1.8

1.0

Tax fees

-

-

0.3

All other fees

-

0.1

-

Total

7.8

7.7

6.2

Summary of adjustments to cash flow statement

(DKK million)

Note

2022

2021

2020

Adjustments for non-cash transactions:

Depreciation, amortization and impairment

3.1, 3.2, 3.3

362

248

259

Share-based compensation expenses

2.3, 4.6

439

310

200

Other

-

(32)

-

Total adjustments for non-cash transactions

801

526

459

Change in operating assets and liabilities:

Receivables

(2,213)

(1,074)

306

Deferred revenue

-

-

513

Other payables

283

304

168

Total change in operating assets and liabilities

(1,930)

(770)

987